Cargando…

PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment

OBJECTIVE: To show the effect of programmed cell death protein-1 ligand level survival times in patients with metastatic non-small cell lung cancer receiving chemotherapy, to determine the relationship between programmed cell death protein-1 ligand level, neutrophil-to-lymphocyte ratio, and platelet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gürsoy, Pınar, Çakar, Burcu, Günenç, Damla, Nart, Deniz, Çinkooğlu, Akın, Katgı, Nuran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish Thoracic Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450090/ https://www.ncbi.nlm.nih.gov/pubmed/35110200 http://dx.doi.org/10.5152/TurkThoracJ.2022.21151

Ejemplares similares

Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience
por: Gürsoy, Pınar, et al.
Publicado: (2022)

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib
por: Katgı, Nuran, et al.
Publicado: (2023)

Pseudomesotheliomatous Primary Squamous Cell Lung Carcinoma: The First Case Reported in Turkey and a Review of the Literature
por: Katgi, Nuran, et al.
Publicado: (2018)

Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
por: Wang, Jin, et al.
Publicado: (2020)

Diagnostic approach in parenchymal lung diseases: transbronchial lung biopsy or cryobiopsy?
por: ÇIRAK, Ali Kadri, et al.
Publicado: (2020)

The Prognostic Value of (18)F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma
por: Agüloğlu, Nurşin, et al.
Publicado: (2022)

A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy()
por: Wang, Jin, et al.
Publicado: (2016)

Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
por: Chen, Yundi, et al.
Publicado: (2021)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy
por: Hong, Yong Joo, et al.
Publicado: (2014)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Nomogram for predicting the survival of gastric adenocarcinoma patients who receive surgery and chemotherapy
por: Wang, Chao-Yang, et al.
Publicado: (2020)

Complication and cost analysis of transbronchial lung cryobiopsy and awake video-assisted thoracic surgery in diagnosis of interstitial lung disease
por: Katgi, Nuran, et al.
Publicado: (2022)

Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
por: Ekin, Zübeyde, et al.
Publicado: (2021)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Efficacy of chest X-ray in the diagnosis of COVID-19 pneumonia: comparison with computed tomography through a simplified scoring system designed for triage
por: Çinkooğlu, Akın, et al.
Publicado: (2021)

Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment()()
por: Vander Jagt, Thomas A., et al.
Publicado: (2018)

PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)
por: Ghosh, Joydeep, et al.
Publicado: (2021)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment
por: Bai, Ming, et al.
Publicado: (2021)

Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
por: Hue, Jonathan J., et al.
Publicado: (2021)

Antifibrotic Effect of Lactulose on a Methotrexate-Induced Liver Injury Model
por: Taskin, Banu, et al.
Publicado: (2017)

Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting
por: Belaroussi, Yaniss, et al.
Publicado: (2023)

Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet’s Uveitis
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2022)

Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
por: Vera-Llonch, Montserrat, et al.
Publicado: (2011)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
por: Yin, Huanhuan, et al.
Publicado: (2020)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018)

Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy
por: Guo, Guifang, et al.
Publicado: (2019)

The Presence of PDL-1 on CD8+ Lymphocytes Is Linked to Survival in Neonatal Sepsis
por: Akhmaltdinova, Lyudmila L., et al.
Publicado: (2022)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
por: Griffiths, Robert I, et al.
Publicado: (2011)

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression
por: Zhang, Chuan, et al.
Publicado: (2023)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy
por: Ha, Gi-Young, et al.
Publicado: (2020)

Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy
por: Fulop, Daniel J., et al.
Publicado: (2023)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?
por: Bišof, Vesna
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_60i31ct0aefmkgob80e23mjmrt